s to complete the assessment of the secondary endpoints of VE by serotype, baseline serostatus and disease severity, including VE against hospitalized dengue.3Part 3 evaluated VE and long-term safety by following participants for an additional two and a half to three years, as per World Health Organization recommendations.4Part 4 evaluated efficacy and safety for 13 months following booster vaccination, and Part 5 evaluated long-term efficacy and safety for one year following the completion of Part 4.3

The trial took place at sites across 8 dengue-endemic countries in Latin America (Brazil, Colombia, Panama, the Dominican Republic and Nicaragua) and Asia (Philippines, Thailand and Sri Lanka) where there are unmet needs in dengue prevention and where severe dengue is a leading cause of serious illness and death among children.5Baseline blood samples were collected from all individuals participating in the trial to allow for evaluation of safety and efficacy based on serostatus
=*=*=*=*=*=
当前为第6/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页